106 related articles for article (PubMed ID: 9493152)
21. Positron emission tomography in neuropsychiatric lupus erythematosus.
Stoppe G; Wildhagen K; Seidel JW; Meyer GJ; Schober O; Heintz P; Künkel H; Deicher H; Hundeshagen H
Neurology; 1990 Feb; 40(2):304-8. PubMed ID: 2132733
[TBL] [Abstract][Full Text] [Related]
22. Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?
Catoggio LJ; Soriano ER; Imamura PM; Wojdyla D; Jacobelli S; Massardo L; Chacón Díaz R; Guibert-Toledano M; Alvarellos A; Saurit V; Manni JA; Pascual-Ramos V; Silva de Sauza AW; Bonfa E; Tavares Brenol JC; Ramirez LA; Barile-Fabris LA; De La Torre IG; Alarcón GS; Pons-Estel BA;
Lupus; 2015 Jul; 24(8):788-95. PubMed ID: 25504653
[TBL] [Abstract][Full Text] [Related]
23. Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE).
Rizos T; Siegelin M; Hähnel S; Storch-Hagenlocher B; Hug A
Lupus; 2009 Apr; 18(4):361-3. PubMed ID: 19276305
[TBL] [Abstract][Full Text] [Related]
24. Positron emission tomography with [(18)F]FDG in the diagnosis of Creutzfeldt-Jakob disease (CJD).
Henkel K; Zerr I; Hertel A; Gratz KF; Schröter A; Tschampa HJ; Bihl H; Büll U; Grünwald F; Drzezga A; Spitz J; Poser S
J Neurol; 2002 Jun; 249(6):699-705. PubMed ID: 12111302
[TBL] [Abstract][Full Text] [Related]
25. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
Gonzalez-Echavarri C; Pernas B; Ugarte A; Ruiz-Irastorza G
Lupus; 2014 Mar; 23(3):323-6. PubMed ID: 24531426
[TBL] [Abstract][Full Text] [Related]
26. White-matter volume reduction and the protective effect of immunosuppressive therapy in systemic lupus erythematosus patients with normal appearance by conventional magnetic resonance imaging.
Xu J; Cheng Y; Chai P; Lu Z; Li H; Luo C; Li X; Li L; Zhou Q; Chen B; Cao J; Xu X; Shan B; Xu L; Wen J
J Rheumatol; 2010 May; 37(5):974-86. PubMed ID: 20231206
[TBL] [Abstract][Full Text] [Related]
27. A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus.
Ercan E; Ingo C; Tritanon O; Magro-Checa C; Smith A; Smith S; Huizinga T; van Buchem MA; Ronen I
Neuroimage Clin; 2015; 8():337-44. PubMed ID: 26106559
[TBL] [Abstract][Full Text] [Related]
28. [Methylprednisolone and cyclophosphamide pulse therapy of severe systemic lupus erythematosus in children].
Hu J; Li CW; Zhang X; Pi SH; Zhao JS; Chen XY; Liu Y
Zhonghua Er Ke Za Zhi; 2003 Jun; 41(6):430-4. PubMed ID: 14748998
[TBL] [Abstract][Full Text] [Related]
29. International survey on the management of patients with SLE. II. The results of a questionnaire regarding neuropsychiatric manifestations.
Tincani A; Brey R; Balestrieri G; Vitali C; Doria A; Galeazzi M; Meroni PL; Migliorini P; Neri R; Tavoni A; Bombardieri S
Clin Exp Rheumatol; 1996; 14 Suppl 16():S23-9. PubMed ID: 9049450
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in systemic lupus erythematosus (SLE) with oral cyclophosphamide.
Jasmin R; Sockalingam S; Shahrizaila N; Cheah TE; Zain AA; Goh KJ
Lupus; 2012 Sep; 21(10):1119-23. PubMed ID: 22433918
[TBL] [Abstract][Full Text] [Related]
31. [Assessment of pharmacological correction in the treatment of patients with systemic lupus erythematosus].
Sultanova TZh
Lik Sprava; 2009; (7-8):86-9. PubMed ID: 20455456
[TBL] [Abstract][Full Text] [Related]
32. Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome.
Jung SM; Moon SJ; Kwok SK; Ju JH; Park KS; Park SH; Kim HY
Lupus; 2013 Aug; 22(9):885-91. PubMed ID: 23846231
[TBL] [Abstract][Full Text] [Related]
33. Active idiopathic Systemic Lupus Erythematosus in a 94-year-old woman necessitating immunosuppressive therapy.
Madge SN; Donegan C
Age Ageing; 2002 Nov; 31(6):489-90. PubMed ID: 12446306
[No Abstract] [Full Text] [Related]
34. Acquired enophthalmos with systemic lupus erythematosus.
Park KR; Seo MR; Ryu HJ; Chi MJ; Baek HJ; Choi HJ
Lupus; 2016 Jan; 25(1):88-92. PubMed ID: 26306741
[TBL] [Abstract][Full Text] [Related]
35. Modern treatment of childhood SLE.
Lehman TJ
Clin Exp Rheumatol; 2001; 19(5):487-9. PubMed ID: 11579704
[No Abstract] [Full Text] [Related]
36. Type B insulin resistance complicated with systemic lupus erythematosus.
Kawashiri SY; Kawakami A; Fujikawa K; Iwamoto N; Aramaki T; Tamai M; Nakamura H; Origuchi T; Ida H; Eguchi K
Intern Med; 2010; 49(5):487-90. PubMed ID: 20190490
[TBL] [Abstract][Full Text] [Related]
37. Urticarial vasculitis in systemic lupus erythematosus: fair response to prednisolone/dapsone and persistent hypocomplementemia.
Nishijima C; Hatta N; Inaoki M; Sakai H; Takehara K
Eur J Dermatol; 1999; 9(1):54-6. PubMed ID: 9920991
[TBL] [Abstract][Full Text] [Related]
38. Hyperacute renal failure as the initial presentation of systemic lupus erythematosus.
Arbel O; Pizov G; Ben-Yehuda A; Rubinow A; Naparstek Y; Amital H
Lupus; 2005; 14(4):331-3. PubMed ID: 15864922
[TBL] [Abstract][Full Text] [Related]
39. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment.
Tanaka E; Harigai M; Tanaka M; Kawaguchi Y; Hara M; Kamatani N
J Rheumatol; 2002 Feb; 29(2):282-7. PubMed ID: 11838845
[TBL] [Abstract][Full Text] [Related]
40. [Neurological presentation of systemic lupus erythematosus].
Romero-López J; Moreno-Carretero MJ; Escriche-Jaime D
Rev Neurol; 1996 Oct; 24(134):1276-8. PubMed ID: 8983729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
